THE ACUTE CORONARY SYNDROME : POSSIBILITY ON THE MODERN THERAPY (literature review. Part II)
https://doi.org/10.51523/2708-6011.2010-7-1-3
Abstract
The information about the modern medical treatment of the acute coronary syndrome was presented in this review
References
1. Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction: an open multicenter randomized trial (The VINO study) / R. Spacer [et al.] // Eur. Heart J. - 2002. - Vol. 23. - P. 230-238.
2. Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trial / S. R. Mehta [et al.] // J.A.M.A. - 2005. - Vol. 293. - P. 2908-2917.
3. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group Low-molecular-weight heparin during instability in coronary artery disease // Lancet. - 1996. - Vol. 347. - P. 561-568.
4. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE 2 study The Antithrombotic Combination Using Tirofiban and Enoxapation / M. Cohen [et al.] // Am. Heart J. - 2002. - Vol. 144. - P. 470-477.
5. The F.R.A.X.I.S. Study Group Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S.(FRAxiparine in Ischemic Syndrome) // Eur. Heart J. - 1999. - Vol. 20. - P. 1553-1562.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes / N. Engl. J. Med. - 1996. - Vol. 335. - P. 775-782.
7. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: result of the Thrombolysis In Myocardial Infarction (TIMI) IIB trial / E. M. Antman [et al.] // Circulation. - 1999. - Vol. 100. - P. 1593-1601.
8. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial / J. J. Ferguson [et al.] // J.A.M.A. - 2004. - Vol. 292. - P. 45-54.
9. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview / J. L. Petersen [et al.] // J.A.M.A. - 2004. - Vol. 292. - P. 89-96.
10. For the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction / E. M. Antman [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1477-1488.
11. Evaluation of prolonged antithrombotic pretreatment («cooling-off» strategy) before intervention in patients with unstable coronary syndromes a randomized controlled trial / F. J. Neumann [et al.] // J.A.M.A. - 2003. - Vol. 290. - P. 1593-1599.
12. Efficacy and Safety of Subcutaneous Enoxaparin in NON-Q-Wave Coronary Events Study Group A comparison of Low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease / M. Cohen [et al.] // N. Engl. J. Med. - 1997. - Vol. 337. - P. 447-452.
13. Comparison of fondaparinux and enoxaparin in acute coronary syndromes / S. Yusuf [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1464-1476.
14. PRISM Study Investigators Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban Platelet receptor Inhibition in Ischemic Syndrome Management / C. Heeschen [et al.] // Lancet. - 1999. - Vol. 354. - P. 1757-1762.
15. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial / A. Kastrati [et al.] // J.A.M.A. - 2006. - Vol. 295. - P. 1531-1538.
16. The platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON)-B Investigators Randomized, placebo-controlled trial of titrated intravenous lamifiban for the acute coronary syndromes // Circulation. - 2002. - Vol. 105. - P. 316-321.
17. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience / M. W. McClure [et al.] // Circulation. - 1999. - Vol. 99. - P. 2892-2900.
18. The CAPTURE Investigators Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study // Lancet. - 1997. - Vol. 349. - P. 1429-1435.
19. Simons, M. L. Effect of glycoprotein IIb/IIIa receptor locker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial / M. L. Simons // Lancet. - 2001. - Vol. 357. - P. 1915-1924.
20. The EPISTENT Investigators Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade Evaluation of Platelet IIb/IIIa Inhibitor for Stenting // Lancet. - 1998. - Vol. 352. - P. 87-92.
21. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. The ACUITY Timing Trial / G. Stone [et al.] // J.A.M.A. - 2007. - Vol. 297. - P. 591-602.
22. Antman, E. M. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial / E. M. Antman // Circulation. - 1994. - Vol. 90. - P. 1624-1630.
23. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators Effects of recombinant hirudin (Lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial // Lancet. - 1999. - Vol. 353. - P. 429-438.
24. Bivalirudin for patients with acute coronary syndromes / G. W. Stone [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2203-2216.
25. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis / S. S. Anand [et al.] / J.A.M.A. - 1999. - Vol. 282. - P. 2058-2067.
26. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study / L. D. Fiore [et al.] / Circulation. - 2002. - Vol. 105. - P. 557-563.
27. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force / M. Hayden [at al.] // Ann. Intern. Med. - 2002. - Vol. 136. - P. 161-172.
28. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation / S. Yusuf [et al.] // N. Engl. J. Med. - 2001. - Vol. 345. - P. 494-502.
29. Optimal timing of coronary artery bypass graft surgery after acute myocardial infarction / J. H. Braxton [et al.] // Circulation. - 1995. - Vol. 92. - P. 66-68.
30. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding / F. K. Chan [et al.] // N. Engl. J. Med. - 2005. - Vol. 532. - P. 238-244.
Review
For citations:
Salivonchik D.P. THE ACUTE CORONARY SYNDROME : POSSIBILITY ON THE MODERN THERAPY (literature review. Part II). Health and Ecology Issues. 2010;(1):13-19. (In Russ.) https://doi.org/10.51523/2708-6011.2010-7-1-3
Views: 294
Email this article 